Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
Among persons with residual invasive disease after treatment of HER2-positive early breast cancer, trastuzumab emtansine resulted in 7-year invasive disease–free survival of 80.8%, as...
Gender-Affirming Surgical Care in Carceral Settings
Beyond ensuring access to gender-affirming surgical care, U.S. carceral facilities can develop health care, housing, and security policies that recognize gender-affirming care as standard...
KRAS Oncoprotein Signaling in Cancer
Recent studies provide new insights into signaling by mutant KRAS, inhibitors of which have provided modest benefits for patients.
The New England Journal of Medicine:...
Open and Endoscopic Carpal-Tunnel Release
Open and endoscopic carpal-tunnel releases are commonly used as the definitive treatment for carpal tunnel syndrome. This video demonstrates these procedures.
The New England Journal...
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age
Zoledronate administered every 12 to 18 months prevents fractures in older women. Ten years after initiation of this trial, zoledronate administered at baseline and...
